Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bi-layer Calcium Carbonate MoA Study
NCT06293326Phase 1Completed
- Sponsor
- Bayer
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of calcium carbonate in gastroesophageal reflux disease (GERD) and dyspepsia (2 arms), sponsored by Bayer. Primary endpoint: Gastric pH levels. Started Mar 2024; status: completed.
02
Drugs
calcium carbonate
03
Conditions
gastroesophageal reflux disease (GERD)dyspepsia
Beyond the preview
Go deeper on NCT06293326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293326.